期刊文献+

丁酸氯维地平静脉脂肪乳剂的质量评价 被引量:5

QualityEvaluation of Clevidipine Butyrate Emulsion for Intravenous Injection
原文传递
导出
摘要 目的:通过对丁酸氯维地平静脉脂肪乳各指标进行检测,对所制备的丁酸氯维地平静脉脂肪乳的质量进行评价,确保制剂的稳定、安全、有效。方法:制备静脉脂肪乳剂,通过测定制剂含量、粒径、电位、pH值、过氧化值、游离脂肪酸值、甲氧基苯胺值等指标对制剂进行质量评价。结果:丁酸氯维地平的峰面积(Y)与浓度(X)在0.1~100μg.mL-1范围内具有良好线性关系,Y=51801X+17659,R2=0.9999(n=3),检测限为0.8ng,所制备的丁酸氯维地平静脉脂肪乳剂的平均含量为97.06%,平均粒径243.2±2.08nm,zeta电位-36.2±0.25,pH 7.03±0.11,过氧化值0.01 mL,游离脂肪酸值0.20±0.01,甲氧基苯胺值2.08±0.07,渗透压306±8.96 mOsmol.Kg-1。结论:所制备丁酸氯维地平脂肪乳的含量符合要求,标示含量在90.0%-110.0%的限度范围,渗透压及pH均与人体血液环境相接近,平均粒径小且分布集中,过氧化值、游离脂肪酸值及甲氧基苯胺值均较低,制备的乳剂性质稳定、重复性好,能够达到国外进口同种制剂的标准。 Objective: To evaluate the quality of clevidipine butyrate emulsion for intravenous injection by detecting each indicator of it, in order to ensure the stability safety and validity of the emulsion. Methods: High pressure homogenization method was used to prepare clevidipine butyrate emulsion for intravenous injection, the quality of clevidipine butyrate emulsion was evaluated by the determination of the content, the mean particle size~ zeta potential, pH value, peroxide value, acid value, and osmotic pressure of clevidipine butyrate emulsion. Results: The peak area of clevidipine butyrate (Y) and concentration (X) in the 0.1-100 μg. mL^-1 range has a good linear relationship within the framework Y=51801X±17659 R2=0.9999(n=3), the detection limit of clevidipine butyrate was 0.8 ng. The mean con- tent of Clevidipine butyrate emulsion was 97.06 %, the mean particle size, Zeta potential, pH value, peroxide value, acid value, anisidine value and osmotic pressure was 243.2± 2.08 nm, -36.2± 0'.25, 2.08± 0.07, 7.03± 0.11, 0.01mL, 0.501± 0.06, and 306± 8.96 mOsmol. Kg^-1 respectively. Conclusion: The content of the clevidipine butyrate emulsion was in the 90.0%-110.0 % range, the osmotic pressure and pH were close to human blood environment, the mean particle size was small and its distribution was concentrated, the peroxide value, free fatty acid value and anisidine value were low, the emulsion prepared was stable, and have good reproducibility, it can reach the standard of the same kind of preparations imported.
出处 《现代生物医学进展》 CAS 2013年第7期1272-1277,共6页 Progress in Modern Biomedicine
关键词 丁酸氯维地平 静脉脂肪乳 质量评价 Clevidipine butyrate Intravenous injection Evaluation
  • 相关文献

参考文献19

  • 1张红卫.新型静脉注射用钙通道拮抗剂——Clevidipine[J].齐鲁药事,2010,29(3):189-190. 被引量:2
  • 2Huan M. Nguyen, Karlene Ma, David Q. Clevidipine for the Treatmentof Severe Hypertension in Adults [J]. Clinical Therapeutics, 2010,32.⑴:11-17.
  • 3Tyler W. Barrett, David L. Schriger. Clevidipine, an Intravenous Dihy-dropyridine Calcium Channel Blocker, Is Safe and Effective forTreatment of Patients With Acute SevereHypertension [J]. Annals OfEmergency Medicine Journal Club, 2009,54(2): 301-306.
  • 4Dennis J. Cada, Terri L. Levien, Danial E. Baker. Clevidipine ButyrateInjectable Emulsion[J]. Hospital Pharmacy, 2008,43(11): 903-908.
  • 5Pollack CV,Varon J, Garrison NA, et al. Clevidipine, an intravenousdihydropyridine calcium channel blocker, is safe and effective for thetreatment of patients with acute severe hypertension [J]. Ann EmergMed, 2009, 53: 329-338.
  • 6Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: Compar-ative studies of clevidipine to nitroglycerin, sodium nitroprusside, andnicardipine for acute hypertension treatment in cardiac surgery pa-tients[J]. Anesth Analg, 2008,107: 1110-1121.
  • 7Levy JH, Mancao MY, Gitter R, et al. Clevidipine effectively andrapidly controls blood pressure preoperatively in cardiac surgery pa-tients: The results of the randomized, placebo-controlled efficacystudy of clevidipine assessing its preoperative antihypertensive effectin cardiac surgery-1[J]. Anesth Analg, 2007,105: 918-925.
  • 8谷福根,吴春芝,刘红在.我国药用静脉注射乳剂的研究进展[J].中国新药杂志,2010,19(16):1415-1421. 被引量:11
  • 9代丽萍,王智民,高慧敏,姜旭,丁广治.蟾皮和华蟾素注射液中蟾蜍噻咛含量测定[J].中国中药杂志,2007,32(3):224-226. 被引量:18
  • 10中华人民共和国药典(2005版一部)[M].北京:化学工业出版社,45-46.

二级参考文献27

共引文献63

同被引文献70

  • 1张会丽,王成港,王春龙.丙泊酚载药脂肪乳的处方及工艺研究[J].天津药学,2007,19(5):31-33. 被引量:6
  • 2VARON J. Treatment of acute severe hypertension: current and newer agents [ J ]. Drugs, 2008,68 ( 3 ) : 283 - 297.
  • 3The Medicines Company. CLEVIPREX ( clevidipine butyrate) injectable emulsion[ EB/OL]. http ://www. themedicinescompany, com/page/cleviprex/1, html, 2009 - 04 - 23.
  • 4US FDA. FDA approvaUetter [ EB/QL ]. http ://www. fda. gov/cder/foi/appletter/2008/022156s0001tr, pdf. html,2008 - 08 - 01.
  • 5RAO J, MCC1EMENTS D J. Formation of flavor oil microemulsions, nanoemulsions and emulsions: influ- ence of composition and preparation method I J ]. J Agric Food Chem ,2011,59 (9) :5026 - 5035.
  • 6前列地尔注射液.WSl-(X-041)-2002Z-2008[s].中国药品标准,2008.
  • 7WASHINGTON C. Stability of lipid emulsions for drug delivery E J J-Adv Drug Deliv Rev, 1996,20 (2) : 131 - 145.
  • 8BERGESE S D, PUENTE E G. Clevidipine bu- tyrate: A promising new drug for the manage- ment of acute hypertension[-J-]. Expert Opinion on Pharmacotherapy, 2010, 11(2): 281-295.
  • 9NGUYEN H M, MA K D. Clevidipine for the treatment of severe hypertension in adults[-J. Clinical Therapeutics, 2010, 32(1): 11-23.
  • 10KEATING G M. Clevidipine: A review of its use for managing blood pressure in perioperative and intensive care settings[-J. Drugs, 2014, 74 (16): 1 947-1 960.

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部